HOOK — Hookipa Pharma Share Price
0.000.00%
Last trade - 00:00- $92.04m
- -$23.93m
- $20.13m
- 30
- 26
- 58
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.02 | ||
| Price to Tang. Book | 1.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -81.86% | ||
| Return on Equity | -84.81% | ||
| Operating Margin | -485.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 11.94 | 19.58 | 18.45 | 14.25 | 20.13 | 32.9 | 14.93 | 21.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Directors
- Jan van de Winkel NEC (60)
- Joern Aldag CEO (62)
- Reinhard Kandera CFO (51)
- Klaus Orlinger EVP (43)
- Roman Necina CTO (53)
- Christine Baker OTH (56)
- Igor Matushansky OTH (48)
- David Kaufman IND (48)
- Michael Kelly IND (64)
- Christoph Lengauer IND (56)
- Julie O Neill IND (55)
- Jean-Charles Soria IND (50)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 15th, 2017
- Public Since
- April 18th, 2019
- No. of Shareholders
- 4
- No. of Employees
- 151
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 98,950,107
- Address
- 350 Fifth Avenue, 72Nd Floor, Suite 7240, NEW YORK, 10118
- Web
- https://www.hookipapharma.com/
- Phone
- Auditors
- PwC Wirtschaftsprufung Gmbh
Upcoming Events for HOOK
HOOKIPA Pharma Inc Annual Shareholders Meeting
HOOKIPA Pharma Inc Annual Shareholders Meeting
Q2 2024 HOOKIPA Pharma Inc Earnings Release
Similar to HOOK
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Hookipa Pharma share price?
As of Today at 19:11 UTC, shares in Hookipa Pharma are trading at $0.93. This share price information is delayed by 15 minutes.
How has the Hookipa Pharma share price performed this year?
Shares in Hookipa Pharma last closed at $0.93 and the price had moved by -31.6% over the past 365 days. In terms of relative price strength the Hookipa Pharma share price has underperformed the S&P500 Index by -44.83% over the past year.
What are the analyst and broker recommendations for Hookipa Pharma?
The overall consensus recommendation for Hookipa Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Hookipa Pharma dividend yield?
Hookipa Pharma does not currently pay a dividend.
Does Hookipa Pharma pay a dividend?
Hookipa Pharma does not currently pay a dividend.
When does Hookipa Pharma next pay dividends?
Hookipa Pharma does not currently pay a dividend.
How do I buy Hookipa Pharma shares?
To buy shares in Hookipa Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hookipa Pharma?
As of the previous close price of $0.93, shares in Hookipa Pharma had a market capitalisation of $92.04m.
Where are Hookipa Pharma shares listed?
Here are the trading details for Hookipa Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HOOK
What kind of share is Hookipa Pharma?
Based on an overall assessment of its quality, value and momentum Hookipa Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hookipa Pharma share price forecast for 2024?
The analyst consensus target price for shares in Hookipa Pharma is $4.33. That is 365.49% above the last closing price of $0.93.
Analysts covering Hookipa Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.36 for the next financial year.
What is the trend in the Hookipa Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hookipa Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +71.88%.
As of the last closing price of $0.93, shares in Hookipa Pharma were trading +38.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hookipa Pharma PE Ratio?
The Hookipa Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hookipa Pharma?
Hookipa Pharma's management team is headed by:
- Jan van de Winkel - NEC
- Joern Aldag - CEO
- Reinhard Kandera - CFO
- Klaus Orlinger - EVP
- Roman Necina - CTO
- Christine Baker - OTH
- Igor Matushansky - OTH
- David Kaufman - IND
- Michael Kelly - IND
- Christoph Lengauer - IND
- Julie O Neill - IND
- Jean-Charles Soria - IND